Franz Hozer1,2,3,4, Samuel Sarrazin3,4, Charles Laidi3,4,5,6, Pauline Favre3,4, Melissa Pauling3,4,5,6, Dara Cannon7, Colm McDonald7, Louise Emsell8,9, Jean-François Mangin10, Edouard Duchesnay10, Marcella Bellani11, Paolo Brambilla12, Michele Wessa13, Julia Linke13, Mircea Polosan14, Amelia Versace15, Mary L Phillips15, Marine Delavest16,17, Frank Bellivier16,17, Nora Hamdani4,5,6, Marc-Antoine d'Albis3,4,5,6, Marion Leboyer4,5,6,18, Josselin Houenou3,4,5,6,18. 1. Department of Psychiatry, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Corentin-Celton, Issy-les-Moulineaux, France. 2. Paris Descartes University, PRES Sorbonne Paris Cité, Paris, France. 3. UNIACT Lab, Psychiatry Team, NeuroSpin Neuroimaging Platform, CEA Saclay, Gif-sur-Yvette, France. 4. INSERM U955, Mondor Institute for Biomedical Research, Team 15, Translational Psychiatry, Créteil, France. 5. Department of Psychiatry, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Mondor, Créteil, France. 6. Fondation FondaMental, Créteil, France. 7. Centre for Neuroimaging & Cognitive Genomics (NICOG), NCBES Galway Neuroscience Centre, National University of Ireland Galway, H91 TK33Galway, Ireland. 8. Translational MRI, Department of Imaging & Pathology, KU Leuven, Leuven, Belgium. 9. Department of Old Age Psychiatry, University Psychiatry Centre, KU Leuven, Leuven, Belgium. 10. UNATI Lab, NeuroSpin Neuroimaging Platform, CEA Saclay, Gif-sur-Yvette, France. 11. UOC Psychiatry, Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Verona, Italy. 12. Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Grand Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. 13. Department of Clinical Psychology and Neuropsychology, Johannes Gutenberg-University Mainz, Mainz, Germany. 14. Grenoble Alpes University, Grenoble Institute of Neuroscience, INSERM U1216, Hôpital Grenoble Alpes, Grenoble, France. 15. Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 16. Department of Psychiatry, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Lariboisière-Fernand Widal, INSERM U705 CNRS UMR 8206, Paris, France. 17. Paris Diderot University, Paris, France. 18. Faculté de Médecine de Créteil, Université Paris Est Créteil, Créteil, France.
Abstract
BACKGROUND: Lithium (Li) is the gold standard treatment for bipolar disorder (BD). However, its mechanisms of action remain unknown but include neurotrophic effects. We here investigated the influence of Li on cortical and local grey matter (GM) volumes in a large international sample of patients with BD and healthy controls (HC). METHODS: We analyzed high-resolution T1-weighted structural magnetic resonance imaging scans of 271 patients with BD type I (120 undergoing Li) and 316 HC. Cortical and local GM volumes were compared using voxel-wise approaches with voxel-based morphometry and SIENAX using FSL. We used multiple linear regression models to test the influence of Li on cortical and local GM volumes, taking into account potential confounding factors such as a history of alcohol misuse. RESULTS: Patients taking Li had greater cortical GM volume than patients without. Patients undergoing Li had greater regional GM volumes in the right middle frontal gyrus, the right anterior cingulate gyrus, and the left fusiform gyrus in comparison with patients not taking Li. CONCLUSIONS: Our results in a large multicentric sample support the hypothesis that Li could exert neurotrophic and neuroprotective effects limiting pathological GM atrophy in key brain regions associated with BD.
BACKGROUND:Lithium (Li) is the gold standard treatment for bipolar disorder (BD). However, its mechanisms of action remain unknown but include neurotrophic effects. We here investigated the influence of Li on cortical and local grey matter (GM) volumes in a large international sample of patients with BD and healthy controls (HC). METHODS: We analyzed high-resolution T1-weighted structural magnetic resonance imaging scans of 271 patients with BD type I (120 undergoing Li) and 316 HC. Cortical and local GM volumes were compared using voxel-wise approaches with voxel-based morphometry and SIENAX using FSL. We used multiple linear regression models to test the influence of Li on cortical and local GM volumes, taking into account potential confounding factors such as a history of alcohol misuse. RESULTS:Patients taking Li had greater cortical GM volume than patients without. Patients undergoing Li had greater regional GM volumes in the right middle frontal gyrus, the right anterior cingulate gyrus, and the left fusiform gyrus in comparison with patients not taking Li. CONCLUSIONS: Our results in a large multicentric sample support the hypothesis that Li could exert neurotrophic and neuroprotective effects limiting pathological GM atrophy in key brain regions associated with BD.
Authors: Ivan Yu Torshin; Olga A Gromova; Konstantin S Ostrenko; Marina V Filimonova; Irina V Gogoleva; Vladimir I Demidov; Alla G Kalacheva Journal: Molecules Date: 2022-03-30 Impact factor: 4.411
Authors: Emilio Bergamelli; Lorenzo Del Fabro; Giuseppe Delvecchio; Armando D'Agostino; Paolo Brambilla Journal: CNS Drugs Date: 2021-11-12 Impact factor: 6.497